SOX11 and neoplasm: In 2009, Brennan et al., using an in silico transcriptomic screen, were the first to describe SOX11 mRNA expression as a prognostic factor for enhanced recurrence-free survival in several histological types of epithelial ovarian cancer, after controlling for tumor stage and grade, with the loss of SOX11 correlating with diminished recurrence-free survival as well as a more aggressive phenotype [33].